210 related articles for article (PubMed ID: 37835053)
1. Substance P and Neurokinin-1 Receptor System in Thyroid Cancer: Potential Targets for New Molecular Therapies.
Isorna I; González-Moles MÁ; Muñoz M; Esteban F
J Clin Med; 2023 Oct; 12(19):. PubMed ID: 37835053
[TBL] [Abstract][Full Text] [Related]
2. The substance P and neurokinin-1 receptor system in human thyroid cancer: an immunohistochemical study.
Isorna I; Esteban F; Solanellas J; Coveñas R; Muñoz M
Eur J Histochem; 2020 Apr; 64(2):. PubMed ID: 32363847
[TBL] [Abstract][Full Text] [Related]
3. The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists.
Muñoz M; González-Ortega A; Rosso M; Robles-Frias MJ; Carranza A; Salinas-Martín MV; Coveñas R
Peptides; 2012 Dec; 38(2):318-25. PubMed ID: 23026680
[TBL] [Abstract][Full Text] [Related]
4. Substance P accelerates the progression of human esophageal squamous cell carcinoma via MMP-2, MMP-9, VEGF-A, and VEGFR1 overexpression.
Mohammadi F; Javid H; Afshari AR; Mashkani B; Hashemy SI
Mol Biol Rep; 2020 Jun; 47(6):4263-4272. PubMed ID: 32436041
[TBL] [Abstract][Full Text] [Related]
5. Neurokinin-1 Receptor Antagonists against Hepatoblastoma.
Muñoz M; Rosso M; Coveñas R
Cancers (Basel); 2019 Aug; 11(9):. PubMed ID: 31466222
[TBL] [Abstract][Full Text] [Related]
6. The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant.
Coveñas R; Rodríguez FD; Robinson P; Muñoz M
Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958914
[TBL] [Abstract][Full Text] [Related]
7. The Neurokinin-1 Receptor Antagonist Aprepitant, a New Drug for the Treatment of Hematological Malignancies: Focus on Acute Myeloid Leukemia.
Muñoz M; Coveñas R
J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32492831
[TBL] [Abstract][Full Text] [Related]
8. Neurotransmitter substance P mediates pancreatic cancer perineural invasion via NK-1R in cancer cells.
Li X; Ma G; Ma Q; Li W; Liu J; Han L; Duan W; Xu Q; Liu H; Wang Z; Sun Q; Wang F; Wu E
Mol Cancer Res; 2013 Mar; 11(3):294-302. PubMed ID: 23345604
[TBL] [Abstract][Full Text] [Related]
9. Triple Negative Breast Cancer: How Neurokinin-1 Receptor Antagonists Could Be Used as a New Therapeutic Approach.
Muñoz M; Rosso M; Coveñas R
Mini Rev Med Chem; 2020; 20(5):408-417. PubMed ID: 31721701
[TBL] [Abstract][Full Text] [Related]
10. Advances in the research and application of neurokinin-1 receptor antagonists.
Hong X; Ma J; Zheng S; Zhao G; Fu C
J Zhejiang Univ Sci B; 2024 Feb; 25(2):91-105. PubMed ID: 38303494
[TBL] [Abstract][Full Text] [Related]
11. Involvement of substance P and the NK-1 receptor in pancreatic cancer.
Muñoz M; Coveñas R
World J Gastroenterol; 2014 Mar; 20(9):2321-34. PubMed ID: 24605029
[TBL] [Abstract][Full Text] [Related]
12. Neurokinin-1 receptor antagonists as antitumor drugs in gastrointestinal cancer: A new approach.
Muñoz M; Coveñas R
Saudi J Gastroenterol; 2016; 22(4):260-8. PubMed ID: 27488320
[TBL] [Abstract][Full Text] [Related]
13. Neurokinin-1 Receptor (NK-1R) Antagonists: Potential Targets in the Treatment of Glioblastoma Multiforme.
Afshari AR; Motamed-Sanaye A; Sabri H; Soltani A; Karkon-Shayan S; Radvar S; Javid H; Mollazadeh H; Sathyapalan T; Sahebkar A
Curr Med Chem; 2021; 28(24):4877-4892. PubMed ID: 33441062
[TBL] [Abstract][Full Text] [Related]
14. Combination Therapy of Chemotherapy or Radiotherapy and the Neurokinin-1 Receptor Antagonist Aprepitant: A New Antitumor Strategy?
Robinson P; Coveñas R; Muñoz M
Curr Med Chem; 2023; 30(16):1798-1812. PubMed ID: 35959620
[TBL] [Abstract][Full Text] [Related]
15. Involvement of substance P and the NK-1 receptor in cancer progression.
Muñoz M; Coveñas R
Peptides; 2013 Oct; 48():1-9. PubMed ID: 23933301
[TBL] [Abstract][Full Text] [Related]
16. The NK-1 receptor antagonist L-732,138 induces apoptosis in human gastrointestinal cancer cell lines.
Muñoz M; Rosso M; Coveñas R
Pharmacol Rep; 2017 Aug; 69(4):696-701. PubMed ID: 28550801
[TBL] [Abstract][Full Text] [Related]
17. The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs.
Munoz M; Covenas R; Esteban F; Redondo M
J Biosci; 2015 Jun; 40(2):441-63. PubMed ID: 25963269
[TBL] [Abstract][Full Text] [Related]
18. A Substance P (SP)/Neurokinin-1 Receptor Axis Promotes Perineural Invasion of Pancreatic Cancer and Is Affected by lncRNA LOC389641.
Ji T; Ma K; Wu H; Cao T
J Immunol Res; 2022; 2022():5582811. PubMed ID: 35600049
[TBL] [Abstract][Full Text] [Related]
19. Neurokinin-1 Receptor Antagonists as a Potential Novel Therapeutic Option for Osteosarcoma Patients.
Robinson P; Rosso M; Muñoz M
J Clin Med; 2023 Mar; 12(6):. PubMed ID: 36983138
[TBL] [Abstract][Full Text] [Related]
20. Cancer progression and substance P.
Coveñas R; Muñoz M
Histol Histopathol; 2014 Jul; 29(7):881-90. PubMed ID: 24535838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
